ReviewFrontiers in endocrinology2015
Progress in the Diagnosis and Classification of Pituitary Adenomas.
Review in Frontiers in endocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Application of artificial intelligence and radiomics in pituitary neuroendocrine and sellar tumors: a quantitative and qualitative synthesis.Neuroradiology · 2022Pooled it
- A Brief Overview of Molecular Biology in Pituitary Adenomas with a Focus on Aggressive Lesions.International journal of molecular sciences · 2025Review
- Immunohistochemical Patterns of Pituitary Adenomas in Southeastern Nigeria, a 10-year Histopathologic Review.The Libyan journal of medicine · 2023Article
- Major Genetic Motifs in Pituitary Adenomas: A Practical Literature Update.World neurosurgery · 2023Review
- Prognostic Factors for Invasiveness and Recurrence of Pituitary Adenomas: A Series of 94 Patients.Diagnostics (Basel, Switzerland) · 2022Article
- Extracting clinical named entity for pituitary adenomas from Chinese electronic medical records.BMC medical informatics and decision making · 2022Article
- Alterations in CD8Pathology oncology research : POR · 2021Article
- Metabolic profiling reveals distinct metabolic alterations in different subtypes of pituitary adenomas and confers therapeutic targets.Journal of translational medicine · 2019Article
- Effect of ASA on pituitary adenomas: is it a matter of survivin?Oncotarget · 2019Article
- Clinical usefulness of 99mTc-HYNIC-TOC, 99mTc(V)-DMSA, and 99mTc-MIBI SPECT in the evaluation of pituitary adenomas.Nuclear medicine communications · 2019Article
- Stem/progenitor cells in pituitary organ homeostasis and tumourigenesis.The Journal of endocrinology · 2018Review
- HMGA2 cooperates with either p27Cell cycle (Georgetown, Tex.) · 2018Article
- Function of cell-cycle regulators in predicting silent pituitary adenoma progression following surgical resection.Oncology letters · 2017Article
- Case Report of a Prolactinoma in a Patient With a NovelJournal of the Endocrine Society · 2017Article
- A 54-Year-Old Male with Multiple Intracranial and Extracranial Masses.Brain pathology (Zurich, Switzerland) · 2017Article
- Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary.Pituitary · 2017Review
- Review
- Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy.CNS oncology · 2016Article
- Gene mutations in Cushing's disease.Biomedical reports · 2016Article
- The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas.The Journal of endocrinology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pituitary adenomas are common neoplasms. Their classification is based upon size, invasion of adjacent structures, sporadic or familial cases, biochemical activity, clinical manifestations, morphological characteristics, response to treatment and recurrence. Although they are considered benign tumors, some of them are difficult to treat due to their tendency to recur despite standardized treatment. Functional tumors present other challenges for normalizing their biochemical activity. Novel approaches for early diagnosis, as well as different perspectives on classification, may help to identify subgroups of patients with similar characteristics, creating opportunities to match each patient with the best personalized treatment option. In this paper, we present the progress in the diagnosis and classification of different subgroups of patients with pituitary tumors that may be managed with specific considerations according to their tumor subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.